Abstract: A hat headliner with temperature control members that is configured to provide a temperature dissimilar to that of its environment at locations along a lower edge of a hat. The present invention includes a body that is either permanently or releasably secured into the head cavity of a hat. The body of the present invention includes a perimeter band member wherein the perimeter band member has formed therein a plurality of receptacles. The plurality of receptacles have an interior volume wherein the interior volume is configured to receive and store temperature members. The temperature members include a housing from a malleable material having a temperature controlling gel therein. The receptacles have a first side and a second side wherein the first side of the receptacle is manufactured from a thermally conductive material and is adjacent a wearer's head.

Abstract: A hat headliner with temperature control members that is configured to provide a temperature dissimilar to that of its environment at locations along a lower edge of a hat. The present invention includes a body that is either permanently or releasably secured into the head cavity of a hat. The body of the present invention includes a perimeter band member wherein the perimeter band member has formed therein a plurality of receptacles. The plurality of receptacles have an interior volume wherein the interior volume is configured to receive and store temperature members. The temperature members include a housing from a malleable material having a temperature controlling gel therein. The receptacles have a first side and a second side wherein the first side of the receptacle is manufactured from a thermally conductive material and is adjacent a wearer's head.

Abstract: The present chitosan-based superfine fiber invention relates to compositions, formulations, and processes that result in numerous significant advantages for the production and use of superfine fiber bioactive matrices in biomedical applications. The present invention relates to superfine, chitosan-based fibers, wherein the chitosan-based fibers have a percentage chitosan content of at least about 20% w/w, and highly conformable and compliant matrices comprising such fibers, processes for their production, and related formulations. The superfine chitosan-based fibers of the invention preferably include microfibers with diameter less than or equal to about 10 microns and micron and submicron fibers that are about 2 microns and less.

Abstract: A hat headliner with temperature control members that is configured to provide a temperature dissimilar to that of its environment at locations along a lower edge of a hat. The present invention includes a body that is either permanently or releasably secured into the head cavity of a hat. The body of the present invention includes a perimeter band member wherein the perimeter band member has formed therein a plurality of receptacles. The plurality of receptacles have an interior volume wherein the interior volume is configured to receive and store temperature members. The temperature members include a housing from a malleable material having a temperature controlling gel therein. The receptacles have a first side and a second side wherein the first side of the receptacle is manufactured from a thermally conductive material and is adjacent a wearer's head.

Abstract: The present chitosan-based superfine fiber invention relates to compositions, formulations, and processes that result in numerous significant advantages for the production and use of superfine fiber bioactive matrices in biomedical applications. The present invention relates to superfine, chitosan-based fibers, wherein the chitosan-based fibers have a percentage chitosan content of at least about 20% w/w, and highly conformable and compliant matrices comprising such fibers, processes for their production, and related formulations. The superfine chitosan-based fibers of the invention preferably include microfibers with diameter less than or equal to about 10 microns and micron and submicron fibers that are about 2 microns and less.

Abstract: The present invention comprises chitosan materials and methods of using carbonic acid for aqueous solubilization of neutralized or pre-treated chitosan gels and provides, among other things, substantially acid salt free composition native final forms without requiring subsequent acid salt elution. The invention includes chitosan-based solid and semi-solid material forms, optionally reinforced with chitosan fibers, such as powders, fibers, films, matrices, sponges, implants, scaffolds, fillers, and hydrogels. Native final forms are produced from chitosan powder solubilized in an aqueous acidic solution, processed to form a high pH hydrated chitosan gel precipitate material that is then neutralized by water washing and re-solubilized substantially to chitosan solution using carbonic acid.

Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.

Abstract: An aqueous chitosan gel system of novel non-scarring, non-interfering, transparent, stable, solubilized chitosan that controls bleeding is described herein. The aqueous chitosan gel system can comprise water, chitosan, an acid, a plasticizer, a rheology modifying agent, an antioxidant stabilizer, an alcohol, and a multi-valent salt. Additional components of the aqueous chitosan gel system can comprise a bifunctional organic acid, a tnfunctional organic acid, a multi-functional organic acid, a phosphoric acid, a polyphosphoric acid and a salt.

Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.

Abstract: The present invention comprises chitosan materials and methods of using carbonic acid for aqueous solubilization of neutralized or pre-treated chitosan gels and provides, among other things, substantially acid salt free composition native final forms without requiring subsequent acid salt elution. The invention includes chitosan-based solid and semi-solid material forms, optionally reinforced with chitosan fibers, such as powders, fibers, films, matrices, sponges, implants, scaffolds, fillers, and hydrogels. Native final forms are produced from chitosan powder solubilized in an aqueous acidic solution, processed to form a high pH hydrated chitosan gel precipitate material that is then neutralized by water washing and re-solubilized substantially to chitosan solution using carbonic acid.

Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.

Abstract: The present invention comprises chitosan materials and methods of using carbonic acid for aqueous solubilization of neutralized or pre-treated chitosan gels and provides, among other things, substantially acid salt free composition native final forms without requiring subsequent acid salt elution. The invention includes chitosan-based solid and semi-solid material forms, optionally reinforced with chitosan fibers, such as powders, fibers, films, matrices, sponges, implants, scaffolds, fillers, and hydrogels. Native final forms are produced from chitosan powder solubilized in an aqueous acidic solution, processed to form a high pH hydrated chitosan gel precipitate material that is then neutralized by water washing and re-solubilized substantially to chitosan solution using carbonic acid.

Abstract: The present invention relates to a compressive band and hemostatic dressing system and related methods of use to provide rapid, non-occlusive bleeding control, arterial injury treatment, and injury protection comfortably and reliably after vascular access procedures. The present invention may comprise some or all of the following elements: a positioner assembly, a compressive cushion component, a compression plate, a strap with a flexible hinge assembly, and a hemostatic dressing. In a preferred embodiment, the systems and methods are applied to treat and ameliorate vascular injury in a transradial percutaneous access procedure and protect against underlying vascular injury; however, the systems and methods described herein may be applied to any vascular access procedure including arm or leg vascular approaches such as the femoral, brachial, dorsalis pedis or tibial blood vessels in arterial or venous line or sheath removal or trocar removal, and in hemodialysis.

Abstract: The present invention relates to a compressive band and hemostatic dressing system and related methods of use to provide rapid, non-occlusive bleeding control, arterial injury treatment, and injury protection comfortably and reliably after vascular access procedures. The present invention may comprise some or all of the following elements: a positioner assembly, a compressive cushion component, a compression plate, a strap with a flexible hinge assembly, and a hemostatic dressing. In a preferred embodiment, the systems and methods are applied to treat and ameliorate vascular injury in a transradial percutaneous access procedure and protect against underlying vascular injury; however, the systems and methods described herein may be applied to any vascular access procedure including arm or leg vascular approaches such as the femoral, brachial, dorsalis pedis or tibial blood vessels in arterial or venous line or sheath removal or trocar removal, and in hemodialysis.

Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.

Abstract: The present invention comprises chitosan materials and methods of using carbonic acid for aqueous solubilization of neutralized or pre-treated chitosan gels and provides, among other things, substantially acid salt free composition native final forms without requiring subsequent acid salt elution. The invention includes chitosan-based solid and semi-solid material forms, optionally reinforced with chitosan fibers, such as powders, fibers, films, matrices, sponges, implants, scaffolds, fillers, and hydrogels. Native final forms are produced from chitosan powder solubilized in an aqueous acidic solution, processed to form a high pH hydrated chitosan gel precipitate material that is then neutralized by water washing and re-solubilized substantially to chitosan solution using carbonic acid.

Abstract: An aqueous chitosan gel system of novel non-scarring, non-interfering, transparent, stable, solubilized chitosan that controls bleeding is described herein. The aqueous chitosan gel system can comprise water, chitosan, an acid, a plasticizer, a rheology modifying agent, an antioxidant stabilizer, an alcohol, and a multi-valent salt. Additional components of the aqueous chitosan gel system can comprise a bifunctional organic acid, a tnfunctional organic acid, a multi-functional organic acid, a phosphoric acid, a polyphosphoric acid and a salt.

Abstract: The present invention comprises chitosan materials and methods of using carbonic acid for aqueous solubilization of neutralized or pre-treated chitosan gels and provides, among other things, substantially acid salt free composition native final forms without requiring subsequent acid salt elution. The invention includes chitosan-based solid and semi-solid material forms, optionally reinforced with chitosan fibers, such as powders, fibers, films, matrices, sponges, implants, scaffolds, fillers, and hydrogels. Native final forms are produced from chitosan powder solubilized in an aqueous acidic solution, processed to form a high pH hydrated chitosan gel precipitate material that is then neutralized by water washing and re-solubilized substantially to chitosan solution using carbonic acid.

Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.

Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.